Bisphosphonates, long used to strengthen bones, may prevent recurrence of early-stage breast cancer in postmenopausal women. In a way, developing low bone-mineral density may have been a lucky break ...

Recently, there has been a trend in the age of women who have been prescribed bisphosphonates (BPs) for the treatment osteoporosis and the prevention of fracture. Now, a recent study has investigated ...

People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a new ...

The use of bisphosphonates, a group of drugs used to prevent hip breakages in women with osteoporosis, is associated with an increased risk of atypical fractures in this joint, understood as those ...

Australia: A new systematic review and meta-analysis has revealed that bisphosphonates may reduce pain in complex regional ...

Women who took a drug holiday (temporary or permanent discontinuation of a medicine) from using bisphosphonates for more than two years have a significantly higher risk of a hip fracture compared to ...

[03-10-2010] Patients and healthcare professionals may have questions about oral bisphosphonate medications and atypical subtrochanteric femur fractures - fractures in the bone just below the hip ...

Research has found that a drug normally given to osteoporosis sufferers could provide effective pain relief to patients with knee and hip osteoarthritis. St George's, University of London research has ...

LONDON (Reuters) - People who take a commonly used class of osteoporosis drugs called bisphosphonates for more than five years may be doubling their risk of developing cancer of the gullet or ...

patient history Ongoing treatment with bisphosphonate therapy may not be needed to prevent future fractures in certain patients due to the sustained effect of the drug. In the long-term treatment of ...

HOUSTON — Women who take a drug holiday from bisphosphonate treatment for a year or longer after 3 or more years of exposure show no greater risk for osteoporosis-related fragility fractures or hip ...

Bisphosphonates are the mainstay of osteoporosis therapy. Extensive clinical evaluation supports their utility in stemming progression of the disease and in reducing fracture risk. In the course of ...